接受他喹单抗治疗的复发性/难治性多发性骨髓瘤患者体重减轻和消化不良

EJHaem Pub Date : 2024-07-03 DOI:10.1002/jha2.971

Syed Naqvi, Asis Shrestha, Marah Alzubi, Jawad Alrawabdeh, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Carolina Schinke, Samer Al Hadidi

{"title":"接受他喹单抗治疗的复发性/难治性多发性骨髓瘤患者体重减轻和消化不良","authors":"Syed Naqvi, Asis Shrestha, Marah Alzubi, Jawad Alrawabdeh, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Carolina Schinke, Samer Al Hadidi","doi":"10.1002/jha2.971","DOIUrl":null,"url":null,"abstract":"<p>Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post-treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight during treatment, with weight loss persisting in about half of the patients post-discontinuation. Weight loss and dysgeusia are important adverse events to consider while on talquetamab treatment. Extending dose intervals can potentially prevent such adverse events and should be studied in future prospective clinical trials.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 4","pages":"789-792"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.971","citationCount":"0","resultStr":"{\"title\":\"Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab\",\"authors\":\"Syed Naqvi, Asis Shrestha, Marah Alzubi, Jawad Alrawabdeh, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Carolina Schinke, Samer Al Hadidi\",\"doi\":\"10.1002/jha2.971\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post-treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight during treatment, with weight loss persisting in about half of the patients post-discontinuation. Weight loss and dysgeusia are important adverse events to consider while on talquetamab treatment. Extending dose intervals can potentially prevent such adverse events and should be studied in future prospective clinical trials.</p>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":\"5 4\",\"pages\":\"789-792\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.971\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.971\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.971","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

他克莫司是一种已获批准的治疗复发/转归多发性骨髓瘤的药物。这项研究调查了消化不良和体重减轻的发生率，同时还调查了停止治疗后症状的可逆性。胃肠不适在15%的患者中普遍存在。在他昔单抗治疗期间，患者体重平均下降了6%，约半数患者在停药后体重持续下降。体重减轻和消化不良是塔雷克单抗治疗期间需要考虑的重要不良反应。延长剂量间隔有可能避免此类不良事件的发生，应在未来的前瞻性临床试验中对并发症和不适感进行研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab

Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post-treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight during treatment, with weight loss persisting in about half of the patients post-discontinuation. Weight loss and dysgeusia are important adverse events to consider while on talquetamab treatment. Extending dose intervals can potentially prevent such adverse events and should be studied in future prospective clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

EJHaem

自引率

0.00%

发文量